The CEO of Sanofi admitted the pharmaceutical giant underperformed in emerging markets last year, after reporting a decline in quarterly sales.» Read More
A check up on the health care sector, with Chris Viehbacher, Sanofi-Aventis CEO, who shares his outlook for 2012.
Chris Viehbacher, CEO of Sanofi, told CNBC, "we have leading positions in nice long life assets, in animal health, in vaccines in emerging markets in diabetes and those will continue to grow because the underlying dynamics are there and that leading position, so I am pretty confident about the medium term outlook."
Sanofi announced it won a patent litigation case over its eloxation cancer drug, with Christopher Viehbacher, Sanofi CEO, and Mad Money host Jim Cramer.
Chris Viehbacher, Sanofi-Aventis CEO discusses President Obama's healthcare plan and future plans for his company.
Sanofi-Aventis concludes its Genzyme acquisition and shares of Best Buy may show a sign of electronics chains losing power, reports CNBC's David Faber.
The Food and Drug Administration rejected another new diet pill on Thursday, the latest setback in the quest to develop treatments for overweight Americans amid the nation’s obesity epidemic.
U.S. drugs giant Abbott Laboratories said it would stop launching new medicines in Thailand in protest at the army-backed government's move to override international drug patents.